Dana-Farber Cancer Institute

The Dana-Farber Cancer Institute is home to leading investigators who have made key discoveries regarding the immune response to cancer. PICI scientists at Dana-Farber are working collaboratively together and within the PICI network to better understand the tumor immune microenvironment across cancer types. The intent is to translate these basic discoveries to the clinic as impactful immunotherapies to fight cancer and improve patient outcomes.

PICI at Dana-Farber Cancer Institute promotes innovation and collaboration in order to advance our understanding of the immune response to cancer and develop novel immunotherapy strategies for the benefit of our patients.

Areas of scientific interest:

• Discovering novel therapeutic targets and their mechanism of action
• Investigating the tumor immune microenvironment to better understand response, resistance and toxicity of immunotherapy
• Developing next generation cellular therapies
• Advancing vaccines as a platform for combination therapies

Elizabeth A. Mittendorf, MD, PhD | Co-Director
F. Stephen Hodi, MD | Co-Director
Kai W. Wucherpfennig, MD, PhD | Co-Director